Caroline Palomeque
Stock Analyst at Maxim Group
(1.26)
# 3,702
Out of 5,111 analysts
10
Total ratings
44.44%
Success rate
-0.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $2.28 | +250.88% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $38.92 | +51.59% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $242.98 | -36.62% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $63.45 | -8.59% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $213.24 | -22.15% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $17.34 | +124.91% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $13.83 | +341.07% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $4.14 | +866.18% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $2.28
Upside: +250.88%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $38.92
Upside: +51.59%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $242.98
Upside: -36.62%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $63.45
Upside: -8.59%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $213.24
Upside: -22.15%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $17.34
Upside: +124.91%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $13.83
Upside: +341.07%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $4.14
Upside: +866.18%